MAP2K7 and non-small cell lung carcinoma: To discriminate between these possibilities, we examined NSCLC cells treated with gemcitabine/cisplatin in combination with MEK inhibitor GSK1120212 (GC/G regimen) and ERK inhibitor SCH772984 (GC/S regimen).